{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-019196","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.997896+00:00","generated_at":"2026-06-29T16:07:28.449739+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Interpace Q2 revenue $11.2M (+105% YoY); gross margin 48% vs 29%, adj EBITDA loss narrows to $0.3M","bullets":["Net revenue $11.2M (+105% vs Q2 2020); six-month revenue $21.0M (+45% YoY).","Gross profit margin 48% (Q2 2020: 29%); loss from continuing ops improved to $3.4M from $5.5M.","Adjusted EBITDA $(0.3)M vs $(4.2)M in prior year; cash collections hit $11.5M in Q2, DSO down 32%.","Cash balance rose to $4.0M at July 31 from $2.8M at Dec 31, 2020; on track for >35% FY revenue growth.","New PLA code 0245U for ThyGeNEXT at $2,919; eviCore coverage for ThyGeNEXT/ThyraMIR effective July 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-019196","json":"https://secwatch.observer/filing/0001493152-21-019196.json","markdown":"https://secwatch.observer/filing/0001493152-21-019196.md","text":"https://secwatch.observer/filing/0001493152-21-019196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315221019196/0001493152-21-019196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315221019196/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T16:07:28.449739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}